Fosun International (00656): Total revenue of 86.96 billion yuan in the first half of 2026, net profit to mother increased 160.3% year-on-year

The Zhitong Finance App learned that on August 27, 2026, Fosun International (00656) and its subsidiaries (collectively, “Fosun” or “Group”) announced today their mid-term (“reporting period”) results for the six months ended June 30, 2026.

In the first half of 2026, Fosun continued to advance the strategy of “slimming down and fitness, focusing on the main business”. Driven by the “twin engines” of innovation and globalization, the operating quality of core industries such as medicine and health, insurance and finance, and cultural tourism consumption steadily improved, and promoted a leap forward in profit quality. During the reporting period, the Group's total revenue reached RMB 86.96 billion, which remained stable despite continued withdrawal from non-strategic non-core assets; industrial operating profit reached RMB 3.69 billion, up 17% year on year; profit attributable to shareholders of the parent company reached RMB 1.72 billion, a sharp increase of 160.3% year on year.

During the reporting period, Fosun's asset base remained stable. The total revenue of its subsidiary Fosun Pharmaceuticals, Yuyuan Co., Fosun Portugal Insurance, and Fosun Travel reached RMB 63.88 billion, accounting for 73.5% of the Group's total revenue. Overseas revenue reached RMB 49.16 billion, up 5.3% year on year. The share of total revenue increased by 3 percentage points to 56.5% over the same period in 2025, fully verifying the effectiveness of globalization.

At the same time, Fosun insists on active and prudent liquidity and debt management to maintain sufficient liquidity safety pads. During the reporting period, the Group completed the withdrawal of non-strategic non-core assets worth more than RMB 12 billion. As of June 30, 2026, cash and bank balances and term deposits were RMB61,214 million, up from the end of 2025; the ratio of total debt to total capital was 55.7%, a further decrease from the end of 2025. A healthy debt ratio and sufficient cash reserves strengthen the Group's ability to withstand risks, while also improving its ability to seize investment opportunities.

Guo Guangchang, Chairman of Fosun International, said, “Over the past few years, Fosun has steadfastly promoted 'slimming and fitness, focused on the main business', and completed systematic adjustments to 'repair the roof on sunny days'. The results of the first half of this year were drastically restored, fully verifying that our strategic choices and continued focus were right. Now, Fosun has returned to a growth trajectory, and we will develop faster and faster on this path in the future.”

Adhere to innovation drive, intensive approval of innovative drugs to accelerate value delivery

In the first half of 2026, Fosun will continue to be innovation-driven and fully embrace AI applications to accelerate the implementation of science and innovation achievements and continue to improve operational efficiency. During the reporting period, Fosun's investment in science and innovation reached RMB 4.2 billion, an increase of 16.7% over the previous year. The global innovation system integrating “independent research and development+investment incubation+ecological cooperation” continued to gain strength, and a number of innovative achievements with global competitiveness emerged.

Focusing on solving unmet clinical needs, the health sector has achieved remarkable results in science and technology innovation. During the reporting period, innovative drugs entered an intensive approval and implementation period, and a total of 20 indications for Fosun Pharmaceutical's 7 innovative drugs were approved for marketing at home and abroad. Among them, fumainine (ruvometinib tablets) was approved to treat children and adolescents with recurrent or refractory Langerhans cell histiocytosis, continuing to overcome gaps in the treatment of rare diseases. In the field of neurodegenerative diseases, Fosun Pharmaceutical continues to promote an innovative layout: on the basis of having obtained development, registration, production and exclusive commercialization rights in China and Hong Kong, Macau, and the 10 agreed Southeast Asian countries, it has further obtained exclusive AR1001 global options, and has the right to exercise the right to expand the licensing area to key markets around the world, including the United States, Europe, and Japan, and act as a marketing license holder in these regions; confirmed clinical trials have progressed steadily since Ganlut capsules were marketed in China. ; The HT001 oral penetrating NLRP3 inhibitor (used to treat Parkinson's disease) introduced by Hengtai Biotech, a shareholder and incubator, has begun phase I clinical trials in Australia.

As a core subsidiary in the health sector, Fosun Pharmaceutical achieved operating revenue of RMB 20.377 billion in the first half of the year. Among them, revenue from innovative drugs increased 13.84% year on year, accounting for 33.35% of pharmaceutical business revenue, becoming the core engine of growth.

In the field of innovative biological drugs, Fosun continued to make breakthroughs in the first half of the year. The perioperative indications for Hans-like gastric cancer developed independently by Fu Hong Hanlin were approved by the China Drug Administration. It became the world's first and only anti-PD-1 monoclonal antibody approved for this indication, pioneering a new paradigm of “de-chemotherapy” after surgery. As a potential best-in-class broad-spectrum anti-tumor PD-L1 ADC, HLX43, has shown initial clinical efficacy of “high efficiency and low toxicity” in multiple solid tumors such as non-small cell lung cancer. Currently, more than 10 single-drug or joint clinical studies have been carried out, with more than 1,500 patients enrolled worldwide, continuously verifying its potential for broad-spectrum treatment in various solid tumors.

During the reporting period, Fu Hong Han Lin showed strong endogenous growth momentum and high-quality hematopoietic capacity, achieving revenue of RMB 3,588.2 billion, an increase of 27.3% over the previous year; net profit of RMB 430.4 million, an increase of 10.3% over the previous year.

Facing the AI wave, Fosun focuses on core business and the global industrial ecosystem, aiming for “implementable productivity” to deeply cultivate AI applications and create real industrial value.

Fosun Pharmaceutical completed the “PharmAid Pharmaceutical Digital Intelligence System v2.0” upgrade, forming four major segments to promote AI empowerment throughout the product pipeline from early R&D to clinical confirmation to post-marketing market life cycle. By the end of the reporting period, Fosun Pharmaceutical had put into operation more than 25 high-value AI projects, and more than 50 scenarios were progressing simultaneously, covering various business lines such as pharmaceutical project evaluation, target prediction, and molecular optimization; 2 new molecules with AI assisted generation and structure have entered the pre-clinical candidate stage. In March 2026, the next-generation rhupH20 excipient injection independently developed by Fuhong Hanlin was clinically approved in China. Relying on its “AI for Science” platform, the original 18-month enzyme molecule design cycle was drastically reduced to 5 months.

In addition to the pharmaceutical sector, AI is already deeply embedded in Fosun's domestic travel, insurance, and intelligent manufacturing businesses. Fosun's travel sector accelerated the launch of “AI G.O” and joined hands with leading technology companies to develop in-depth cooperation in the three directions of AI empowering guest experience, transforming cloud and AI native platforms, and global growth. Combining the resource requirements brought about by AI technology, the Hainan mining industry quickly lays out upstream core resources such as fluorite ore.

Deep-global operations improve quality and efficiency, and domestic and foreign insurance companies are improving across the board

Relying on the industrial layout and in-depth operation in more than 40 countries and regions around the world, Fosun is comprehensively promoting the “China's ability to graft global resources” strategy, deeply integrating China's manufacturing capabilities, service capabilities and innovation dividends with the global market. During the reporting period, the Group's overseas revenue reached RMB 49.16 billion, accounting for 56.5% of total revenue.

In the first half of 2026, the global capabilities of Fosun's enterprises continued to increase, and the “overseas” business continued to achieve major breakthroughs.

In the field of medicine and health, Fosun Pharmaceutical's overseas business revenue increased 16.45% year on year, accounting for 31.30% of revenue, up 3.11 percentage points year on year, and the revenue structure continued to be optimized. Fuhong Hanlin H Drug Hans Form has been approved for three new indications in the EU. HLX11 (pertuzumab injection) has also been approved for marketing in the EU, and two HLX14 (desumab injection) products have been approved and commercialized in Canada. Up to now, 10 Fuhong Hanlin products have been approved for marketing in more than 60 countries and regions around the world, covering a wide range of Asia, Europe, Latin America, North America and Oceania, benefiting more than 1.1 million patients. Fosun Health continues to promote the internationalization process, actively expand markets such as Indonesia, Bangladesh, Mongolia, Hong Kong and Macau, and build an open, stable and professional international medical cooperation network. Furthermore, the Foshan Fosun Chancheng Hospital International Medical Center building has been newly commissioned to establish a closed loop of international medical services throughout the entire process.

In the consumer and cultural tourism sector, in the first half of 2026, Yuyuan Yuyuan Co., Ltd.'s revenue in Hong Kong and Macau in China reached RMB 532 million, an increase of 285.83%; revenue from the Japanese market reached RMB 306 million, an increase of 6.09% over the previous year. The overseas expansion of the jewelry sector has achieved outstanding results. Laomiao has added 5 new Hong Kong, Macau, overseas and duty-free stores. Currently, the total number of Hong Kong, Macau, overseas and duty-free channels has reached 15. Club Med continues to advance its global destination layout. Club Med Mediterranean Daylight Ark Hangzhou Longwu Resort officially opened in April 2026, and Club Med Mediterranean Club South Africa Seaside and Safari Resort began trial operation in July 2026.

In the field of intelligent manufacturing, the Hainan mining “Malibu Guni lithium mine+Hainan Xingzhihai lithium salt processing” integrated industrial chain operated steadily and became the core engine for the company's performance growth. In the first half of the year, three batches of 70,000 tons of lithium concentrate were delivered from Mali in Africa to Yangpu Port in Hainan, China. Wansheng Co., Ltd.'s phosphate flame retardant project at its base in Thailand was successfully put into operation, filling the gap in overseas manufacturing and injecting new resilience into the global supply chain.

As the globalization strategy progressed further, the overall performance of Fosun's domestic and overseas insurance companies improved in the first half of 2026. By the end of the reporting period, Fosun Portugal Insurance's overall share of the Portuguese market reached 30.1%. The international business accounted for 26.7% of the total consolidated business scale, and the total gross premiums in the overseas market reached €1,035 billion. During the reporting period, despite losses caused by many storms in Portugal, Fosun Portugal Insurance's net profit to mother reached 165 million euros, an increase of 23.8% over the previous year.

Dingrui Reinsurance maintains steady performance with a high-quality customer base, strict underwriting discipline, and a global business layout. During the reporting period, reinsurance revenue and gross premiums increased by 25.0% and 11.8%, respectively, and recorded net profit of USD 89.7 million after tax. With sound financial strength and a continuously improving market position, Moody's upgraded Dingrui Reinsurance's rating from Baa1 to A3 in April 2026, with a “stable” rating outlook.

Domestically, Fosun Prudential Life's premium for the first half of 2026 reached RMB 8.38 billion, up 52.2% year on year; net profit of RMB 780 million, up 270% year on year. Net profit for the first half of the year exceeded the full year of 2025. Fosun United Health Insurance's revenue increased 36.2% year over year, achieving net profit of RMB 572 million.

Adhering to business for good, MSCI ESG rating upgraded to the highest level of AAA

Fosun continued to receive international recognition in the environmental, social and governance (ESG) field during the reporting period. The MSCI ESG rating was upgraded to the highest level of AAA, and was once again successfully selected in the S&P Global “Sustainability Yearbook 2026” and ranked as the best 1% in the “Sustainability Yearbook (China Edition) 2026”. Furthermore, the FTSE ESG rating continues to lead the global industry and the average of Chinese companies, and has been selected as a component of the FTSE4Good Index Series (FTSE4Good Index Series) for five consecutive years.

Fosun continues to contribute to the “China Program” to aid Africa in fighting malaria. By the end of the reporting period, the total global supply of injectable artemisinin developed independently by Fosun Pharmaceutical had exceeded 460 million, treating more than 92 million people with severe malaria. The “Seasonal Malaria Drug Prevention Program”, which uses SPAQ-CO series products as the core drug, has benefited more than 330 million children in Africa.

The “Village Doctor Program” initiated by the Fosun Foundation continues to cover 78 project counties in 16 provinces, cities, and autonomous regions, protecting 25,000 rural doctors, and benefiting 3 million rural families and 16.34 million rural people. In the first half of 2026, more than 12,590 copies of group accident insurance and critical illness insurance were applied for group accident insurance and critical illness insurance for rural doctors in the project counties, and 59 health rooms (hospitals) were intelligently upgraded to help 263 village doctors obtain the rural general practice assistant physician qualification certificate; the 2.0 version of the “AI Village Medical Assistant” service launched in May had a 100% success rate, and village doctor user satisfaction reached 92%.

Looking forward to the future, Guo Guangchang said, “The restoration of performance in the first half of the year was not an accident; it was an inevitable result of Fosun adhering to the long-term principle and continuing to cultivate its main business. Facing the future, we will continue to promote innovation-driven and global development around advantageous industries. Following a definitive path, we are confident that we will gradually restore the profit scale of RMB 10 billion.”